Get started
Author

Heidi Wirtz

Observed name: Wirtz, Heidi
Observed institution: Pfizer (United States)
OpenAlex ID: A5127790286
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · Matthew D. Galsky, Begoña P. Valderrama, et al. · Journal of Clinical Oncology · 32
Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
2026 · Thomas Powles, Michiel S. Van Der Heijden, et al. · Journal of Clinical Oncology · 3
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · Christopher J. Hoimes, Matthew D. Galsky, et al. · Journal of Clinical Oncology
Additional file 1: of Anticholinergic medication use and falls in postmenopausal women: findings from the womenâ s health initiative cohort study
2016 · Marcum, Zachary, Wirtz, Heidi, et al. · Figshare
Additional file 2: Figure S1. of Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis
2016 · Block, Geoffrey, Yusuf, Akeem, et al. · Figshare
Works count: 5
Citation count: 34
H-index: 2
I10-index: 1
Year
Topic
Type